After several years of practice, the thinking of medical insurance negotiations has completely changed.

Drug prices still need to be controlled, and exchanging volume for price is the unshirkable responsibility of the Medical Insurance Bureau as a large buyer. However, the tone of the negotiations has changed.

In the past few years, the Medical Insurance Bureau emphasized "soul bargaining"; but in this year's medical insurance negotiations, the official tone of the Medical Insurance Bureau has become "two-way running."

"Going in both directions" means no longer just pursuing low prices, but negotiating with a reasonable price and stable expectations. For medical insurance, including more high-quality drugs through negotiations with pharmaceutical companies is to strive for the maximum benefits for insured persons on the basis of maintaining the stable operation of the fund; and for pharmaceutical companies, entering medical insurance can usually show significant benefits. By increasing sales, the commercialization process can be smoother, and R&D can be better supported by exchanging price for volume.

In fact, at the press conference of the Medical Insurance Bureau, we can also hear many times the statement of helping companies obtain reasonable profits. Therefore, the expectations for truly innovative pharmaceutical companies in the entire medical insurance negotiation will become increasingly clear.

In addition, in addition to medical insurance, incremental payment policies are also being actively explored. The National Medical Insurance Bureau stated that with the rapid development of medical technology, some expensive cell therapy and gene therapy drugs have been launched one after another, which cannot be fully supported by the basic medical insurance system alone. The National Medical Insurance Bureau is working hard to build a "1+3+N" multi-level medical care The security system will expand greater development space for innovative drugs and better meet the multi-level medical security needs of the people.

Although it is a fact that the domestic payment environment is not as good as that of the United States, it is also a fact that it continues to improve. This is undoubtedly the biggest good news for the innovative pharmaceutical and device industry.

https://mp.weixin.qq.com/